PMC6370167_01
Magnetic resonance imaging (MRI). Shown is the MRI scan of the patient when he 1st visited our hospital. A mass in the right abdomen can be seen. MRI = magnetic resonance imaging
medi-98-e14060-g001.jpg
PMC6370167_01_medi-98-e14060-g001.jpg
F1
After an Oncological Committee evaluation, magnetic resonance imaging (MRI) was performed (Fig. 1).
Postoperative pathology after a 2nd surgery in our hospital. (A) Hematoxylin and eosin stainingshow spindle-shaped or polygonal cells with enlarged nuclei. A number of mitoses can be seen in the high-power fields (HPFS) (Original magnification: 40 x 10). (B-D) Immunohistochemistry shows the cells are positive for (B) CD117, (C) Dog-1 and (D) Ki-67 Li is about 30% (Original magnification:4 x 10). HPFS = high-power fields.
medi-98-e14060-g002.jpg
PMC6370167_01_medi-98-e14060-g002.jpg
F2
The Ki-67 labeling index was about 30% (Fig. 2A-D).
Computed tomography of the abdominal mass. Shown is a CT scan from November 2013. (A) A recurring mass can be seen in the left abdomen, whichshows (B) a significant decreasein size after 3 months of sunitinib therapy, and (C) nearly complete clinical remission after 7 months of the therapy. (D) The complete remission is maintained in December 2016, but (E) the tumor recurs again in August 2017. (F) The most recent view in September 2017. CT = computed tomography.
medi-98-e14060-g004.jpg
PMC6370167_01_medi-98-e14060-g004.jpg
F3
A CT scan 4 months after the surgery revealed a mass in the left abdomen (Fig. 3A), indicative of a relapse. Three months after sunitinib treatment was started, the tumor showed a significant decrease in size (Fig. 3B). Seven months later, the mass showed nearly clinical CR (Fig. 3C), which continued until December 2016 (Fig. 3D). The CT showed a recurrence again in August 2017 (Fig. 3E), and the tumor further enlarged by September 2017 (Fig. 3F).